AU2021238639A1 - Ginsenoside compositions - Google Patents

Ginsenoside compositions Download PDF

Info

Publication number
AU2021238639A1
AU2021238639A1 AU2021238639A AU2021238639A AU2021238639A1 AU 2021238639 A1 AU2021238639 A1 AU 2021238639A1 AU 2021238639 A AU2021238639 A AU 2021238639A AU 2021238639 A AU2021238639 A AU 2021238639A AU 2021238639 A1 AU2021238639 A1 AU 2021238639A1
Authority
AU
Australia
Prior art keywords
ginsenosides
extract
composition
weigh
total
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021238639A
Other languages
English (en)
Inventor
Pascale Elizabeth Renée FANÇA-BERTHON
Romain LECOZANNET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Givaudan SA
Original Assignee
Givaudan SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2004121.6A external-priority patent/GB202004121D0/en
Priority claimed from GBGB2005288.2A external-priority patent/GB202005288D0/en
Application filed by Givaudan SA filed Critical Givaudan SA
Publication of AU2021238639A1 publication Critical patent/AU2021238639A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
AU2021238639A 2020-03-20 2021-03-17 Ginsenoside compositions Pending AU2021238639A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2004121.6A GB202004121D0 (en) 2020-03-20 2020-03-20 Improved compositions
GB2004121.6 2020-03-20
GBGB2005288.2A GB202005288D0 (en) 2020-04-09 2020-04-09 Improved compositions
GB2005288.2 2020-04-09
PCT/EP2021/056788 WO2021185890A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions

Publications (1)

Publication Number Publication Date
AU2021238639A1 true AU2021238639A1 (en) 2022-09-15

Family

ID=75108332

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021238639A Pending AU2021238639A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions
AU2021238643A Pending AU2021238643A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021238643A Pending AU2021238643A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions

Country Status (8)

Country Link
US (2) US20230124503A1 (https=)
EP (2) EP4121061A1 (https=)
JP (2) JP7850670B2 (https=)
CN (2) CN115315266A (https=)
AU (2) AU2021238639A1 (https=)
BR (2) BR112022015826A2 (https=)
CA (2) CA3174699A1 (https=)
WO (2) WO2021185890A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021185890A1 (en) * 2020-03-20 2021-09-23 Givaudan Sa Ginsenoside compositions
CN117224553B (zh) * 2023-11-02 2025-08-12 浙江大学 人参皂苷Rg3在制备治疗或预防肠道病毒感染的药物中的应用
CN117752706B (zh) * 2023-12-20 2025-10-14 浙江天皇药业有限公司 西洋参炮制品在制备治疗甲状腺功能减退症药物中的应用
WO2025261873A1 (en) 2024-06-20 2025-12-26 Givaudan Sa Improvements in or relating to compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202731A1 (en) * 2003-04-08 2004-10-14 Gow Robert T. Rosmarinic acid composition
US9956241B2 (en) * 2009-05-04 2018-05-01 Naturex, S.A. Application of American Ginseng to enhance neurocognitive function
US20100278944A1 (en) 2009-05-04 2010-11-04 Naturex, S.A. Application of american ginseng to enhance neurocognitive function
US10456436B2 (en) * 2013-11-04 2019-10-29 Wen Luan Wendy Hsiao Use of herbal saponins to regulate gut microflora
JP7223754B2 (ja) 2017-07-18 2023-02-16 セネッセンス ライフ サイエンセズ プライベート リミテッド 認知機能の低下の治療および予防、また神経機能の保持に関する組成物およびその方法。
CN110613802A (zh) 2018-06-20 2019-12-27 珠海岐微生物科技有限公司 白茅根大黄炭三七组合物及其在调节肠道微生物中的用途
CN109432304A (zh) * 2018-12-03 2019-03-08 杭州胡庆余堂药业有限公司 一种含铁皮石斛组合物在药物制备中的应用
WO2021185890A1 (en) 2020-03-20 2021-09-23 Givaudan Sa Ginsenoside compositions

Also Published As

Publication number Publication date
CA3174698A1 (en) 2021-09-23
US20230129389A1 (en) 2023-04-27
CN115315264A (zh) 2022-11-08
JP7808042B2 (ja) 2026-01-28
BR112022016241A2 (pt) 2022-10-11
US20230124503A1 (en) 2023-04-20
BR112022015826A2 (pt) 2022-10-04
EP4121061A1 (en) 2023-01-25
EP4121076A1 (en) 2023-01-25
WO2021185890A1 (en) 2021-09-23
AU2021238643A1 (en) 2022-10-20
JP2023518064A (ja) 2023-04-27
WO2021185897A1 (en) 2021-09-23
JP7850670B2 (ja) 2026-04-23
JP2023519189A (ja) 2023-05-10
CA3174699A1 (en) 2021-09-23
CN115315266A (zh) 2022-11-08

Similar Documents

Publication Publication Date Title
US20230129389A1 (en) Ginsenoside compositions
US6083932A (en) Pharmaceutical compositions derived from ginseng and methods of treatment using same
Liu et al. Microbiome and metabolome integrally reveal the anti-depression effects of Cistanche deserticola polysaccharides from the perspective of gut homeostasis
Tan et al. Antidepressant shugan jieyu capsule alters gut microbiota and intestinal microbiome function in rats with chronic unpredictable mild stress-induced depression
WO2022127934A1 (zh) 人参皂苷在改善肠道菌群结构和/或肠屏障功能的应用
Lee et al. Changes in the ginsenoside content during the fermentation process using microbial strains
CN102233009B (zh) 一种促进神经再生的中药组合物及其制备方法和应用
Wei et al. Mahuang Fuzi Xixin decoction ameliorates allergic rhinitis and repairs the airway epithelial barrier by modulating the lung microbiota dysbiosis
Ge et al. Sishen pill ameliorates dextran sulfate sodium (DSS)‐induced colitis with spleen‐kidney yang deficiency syndromes: role of gut microbiota, fecal metabolites, inflammatory dendritic cells, and TLR4/NF‐κB pathway
US11707497B2 (en) Methods and compositions with purified Bombyx mori cocoon silk peptide fiber and refined Buglossoides arvensis seed oil providing anti-inflammatory effects and neuroprotection for disease states
Wang et al. High intestinal isoleucine is a potential risk factor for food allergy by regulating the mTOR/AKT pathway in dendritic cells
Li et al. Hemp seed oil ameliorates CFA-induced rheumatoid arthritis in rats by improving metabolic abnormalities and gut microflora
US11357810B2 (en) Compositions with purified Bombyx mori cocoon silk peptide fiber and refined Buglossoides arvensis seed oil having synergistic effects for improving memory, focus, and cognitive function, and related methods
Wei et al. Stilbene glucoside, a putative sleep promoting constituent from Polygonum multiflorum affects sleep homeostasis by affecting the activities of lactate dehydrogenase and salivary alpha amylase
Ren et al. Comprehensive metagenomic and lipidomic analysis showed that baicalin could improve depressive behaviour in atherosclerotic mice by inhibiting nerve cell ferroptosis
CN117018017A (zh) 低温熟化黑参低聚糖在制备预防或治疗认知障碍药物中的应用
Lemerond et al. Panax ginseng Meyer Herbal Preparation HRG80 for Preventing and Mitigating Stress-Induced Failure of Cognitive Functions in Healthy Subjects
CN114832006A (zh) 人参皂苷Rh4在制备用于抑制睡眠的药物中的用途
TWI810645B (zh) 乳桿菌組合物及其改善抗生素造成之焦慮症的用途
WO2015029134A1 (ja) ジンセノサイド組成物
Chi Study on biofate and antidepressive mechanism of fructooligosaccharides from Morinda officinalis
KR100656888B1 (ko) 뇌 선조체 병소 유발물질로부터 뇌 선조체 보호효과를 갖는 진세노사이드 함유 조성물
Pan et al. Huangqi Guizhi Wuwu Decoction promotes neuroprotection and functional recovery after ischemic stroke via activation of the PI3K/Akt/mTOR signaling pathway and modulation of microglial polarization
Zhang Sleep-promotion of probiotics-fermented Gastrodia elata Bl.: Chemical variation and omics exploration.
EP4590285A1 (en) Phlorotannins and alpha-fucans to treat type 2 diabetes mellitus